Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Revance Therapeutics, Inc. (RVNC) Investors and Encourages Investors to Contact the Firm Before February 8, 2022

Business Wire January 7, 2022

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important February 8 Deadline in Securities Class Action - RVNC

Newsfile January 7, 2022

Thornton Law Firm Reminds Revance Therapeutics (RVNC) Investors of Securities Class Action Lawsuit

Newsfile January 7, 2022

Investor Action Notice: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 7, 2022

Revance Provides Preliminary Fourth Quarter and Full Year 2021 Financial Results and a Corporate Update

Business Wire January 7, 2022

Revance Therapeutics Shareholder Notice

Newsfile January 6, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC

PR Newswire January 6, 2022

Investor Action Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 6, 2022

Revance Therapeutics Shareholder Alert

Newsfile January 5, 2022

REVANCE THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC

PR Newswire January 5, 2022

RVNC Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of LP February 8, 2022 Deadline in Securities Fraud Class Action Lawsuit

Newsfile January 5, 2022

Revance Therapeutics Deadline Alert

Newsfile January 4, 2022

RVNC Alert: Thornton Law Firm Reminds Revance Therapeutics Investors of Securities Class Action Lawsuit

Newsfile January 4, 2022

Investor Action Notice: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 4, 2022

RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire January 4, 2022

RVNC Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Revance Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

Business Wire January 4, 2022

REVANCE THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Revance Therapeutics, Inc. in the United States District Court for the Northern District of California

PR Newswire January 4, 2022

Lead Plaintiff Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc.

PR Newswire January 3, 2022

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Revance Therapeutics, Inc. a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNC

PR Newswire January 3, 2022

Investor Action Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 3, 2022